Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01433250
- Testing
- AIN457
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
- Trial name
- NCT00670449
- Testing
- Fingolimod
- Where
- 20 sites in Japan
- Volunteers
- 143 people
- Sponsor
- Novartis
Relapsing Multiple Scelrosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS II (NCT02792231)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 178 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three…
- Trial name
- MoveS-it (NCT04602390)
- Testing
- ANK-700
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Anokion SA
Multiple Sclerosis
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic…
- Trial name
- LEMTRADA-ITP (NCT03784898)
- Testing
- Blood draw for future biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Cerebral Palsy, Multiple Sclerosis
Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery
The purpose of this study is to record signatures from the fluid surrounding the spinal cord from people who have an implanted drug infusion system.
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Traumatic Brain Injury, Spinal Cord Injury
- Trial name
- NCT01117090
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- MedtronicNeuro
Amyotrophic Lateral Sclerosis
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01709149
- Testing
- CK-2017357, Riluzole
- Where
- 75 sites in United States, Canada and 6 more
- Volunteers
- 711 people
- Sponsor
- Cytokinetics
Multiple Sclerosis, Walking Impairment
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
- Trial name
- NCT03567057
- Testing
- ADS-5102, 274 mg
- Where
- 92 sites in United States, Canada
- Volunteers
- 424 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Relapsing Remitting Multiple Sclerosis
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same…
- Trial name
- EARLiMS (NCT01498887)
- Testing
- Fingolimod (FTY720)
- Where
- 47 sites in Australia, Spain
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- FREEDOMS II (NCT00355134)
- Testing
- Fingolimod
- Where
- 112 sites in United States, Australia and 6 more
- Volunteers
- 1,083 people
- Sponsor
- Novartis
Multiple Sclerosis
Duloxetine for Multiple Sclerosis Pain
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple…
- Trial name
- NCT00755807
- Testing
- Duloxetine Hydrochloride (HCI)
- Where
- 22 sites in United States, Belgium and 2 more
- Volunteers
- 239 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.
- Trial name
- NCT00370071
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Bayer
Multiple Sclerosis
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis
- Trial name
- NCT00207727
- Testing
- CNTO 1275
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Multiple Sclerosis
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
- Trial name
- NCT00483652
- Testing
- Fampridine-SR
- Where
- 40 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Neurogenic Bladder, Multiple Sclerosis
Brain Targets in Patients With Bladder Emptying Difficulties
The goal of this study is to identify brain centers specifically associated with "initiation of voiding" in patients with neurogenic bladder dysfunction.
- Conditions
- Neurogenic Bladder, Multiple Sclerosis, Voiding Dysfunction
- Trial name
- NCT03574610
- Testing
- Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
Multiple Sclerosis
Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis
Twenty four relapsing-remitting multiple sclerosis (RRMS) patients over the age of 18, with similar degree of disability, and with an evolution of at last 6 months, who are in first-line immunomodulatory therapy and have a stable…
- Trial name
- NCT02280096
- Testing
- 4-aminopyridine
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Multiple Sclerosis
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).
- Trial name
- TEMSO (NCT00134563)
- Testing
- Teriflunomide
- Where
- 21 sites in United States, Austria and 19 more
- Volunteers
- 1,088 people
- Sponsor
- Sanofi